EPGNY Stock UPDATES Epigenomics Ag (EPGNY) 23.8500 09/11/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 11, 2014 at 3:51 PM

Epigenomics Ag (EPGNY) 23.8500 $EPGNY

Epigenomics AG Begins Trading on OTCQX®
PR Newswire - Fri Jan 10, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Epigenomics AG (OTCQX: EPGNY; Frankfurt Stock Exchange: ECX, Prime Standard), a German-American molecular diagnostics company developing and commercializing products for cancer screening and diagnosis, has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®, the best marketplace with qualified companies.

S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poor's Factual Stock Reports
PR Newswire - Fri Sep 06, 9:55AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Epigenomics AG.

Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The World Market For Personalized Medicine: Key Competitors Covered and Forecasts Provided to 2016
M2 - Wed Jul 17, 6:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3z6sk/personalized) has announced the addition of the "The World Market For Personalized Medicine" report to their offering. This world market report includes important core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. This business report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies. Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a ba

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lufax's Q3 Struggles: Rising Losses Amid Income Drop

Noteworthy Changes in Lufax's Financial Landscape Diving into Lufax's third quarter of 2026, it's clear as day that the numbers are drawing a grim picture. Lufax, a heavyweight in financial services for small business owners in China, announced unflattering financial results. The headline here? A net loss of RMB1,494 million, far from the RMB380 million lost the previous...

USDA Loans in Pampa: Clearing Up Misconceptions

Understanding USDA Loans in Pampa When it comes to buying a home in Pampa, Texas, there's a lot of chatter about USDA loans, and a fair bit of confusion too. Now, real estate expert Patti Hudson is cutting through the noise and setting the record straight, making sure families know all the facts before diving into the housing market. Not Just for Rural Areas Let's squash...

CapCut Leads 2026 AI Image Tools for Creatives

CapCut Emerges as a Go-To in AI Imagery There's no better feeling than striking gold in a flooded market. CapCut's got folks buzzing in 2026 for its top-tier AI image creation tools, according to Expert Consumers' latest rankings. On the surface, it might just seem like another tech gimmick, but dig a bit deeper, and you'll see why it's a game changer. From adland to...

New Ambulatory Surgery Center in Alabama Breaks Ground

Breaking New Ground: USOP and SOS Lead the Charge You can almost hear the construction noise starting up in Montgomery, Alabama, where U.S. Orthopaedic Partners (USOP) and Southern Orthopaedic Surgeons (SOS) have just launched an ambitious new project. They're not just cutting ceremonial ribbons; they're slicing into the future of orthopedic care in Central Alabama. The...

Liz Parrish's Bold Take on Gene Therapy and Aging

A Mother's Quest: From Personal Struggles to Professional Breakthroughs Never underestimate a mother's determination. When Liz Parrish's son was diagnosed with Type 1 diabetes, it sparked a relentless drive in her to find answers beyond conventional medicine. This journey led Parrish, CEO of BioViva Sciences USA Inc., not just into the cutting-edge world of gene therapy,...

oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

Seasonal Hiring Booms as Firms Eye Long-Term Talent

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Red Robin Faces Board Shakeup and Financial Strategy Shift

Turbulence on the Board But Strategic Moves on Track Well, it's not every day you hear about a double departure from Red Robin's board, right on the heels of some big financial reshuffling. Two directors, James C. Pappas and Christopher Martin, decided to abandon ship effective October 23, 2026. Given their ties to JCP Investment and Jumana Capital, this isn't just a...

Medical Device Manufacturing: $135B Market by 2031

Skyrocketing Demand in Medical Device Manufacturing You're looking at a market that's gearing up to hit a whopping $135.47 billion by 2031. That's a big leap from its $85.59 billion stature in 2026, showing a strong 9.6% compound annual growth rate (CAGR). Now, if that doesn't get your investor rollercoaster senses tingling, I don't know what will. Key Growth Drivers The...

UPM Defies Market Challenges: Strong Q3 Cash Flow

UPM's Impressive Q3 Performance Amidst Challenges UPM-Kymmene Corporation just dropped their Q3 numbers, and let me tell ya, there's a lot to digest. In the face of some pretty gnarly market conditions—think destocking and those pesky cost inflations—they've managed to pull a rabbit out of the hat with strong cash flow. That's not a small feat, folks; it's a damn...